We are live on ! Find out more
ACM

Altium Capital Management Portfolio holdings

AUM $42M
This Fund
S&P 500
This Quarter Est. Return
+33.27%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$273M
AUM Growth
+$22.8M
Cap. Flow
+$4.67M
Cap. Flow %
1.71%
Top 10 Hldgs %
26.58%
Holding
166
New
40
Increased
8
Reduced
21
Closed
31

Top Buys

Rank Stock Value
1
BLRX
BioLineRX
BLRX
+$5.92M
2
PLRX icon
Pliant Therapeutics
PLRX
+$4.11M
3
NSTG
NanoString Technologies, Inc.
NSTG
+$3.89M
4
RMD icon
ResMed
RMD
+$3.87M
5
BCAB icon
BioAtla
BCAB
+$3.62M

Top Sells

Rank Stock Value
1
STAA icon
STAAR Surgical
STAA
+$5.32M
2
LNTH icon
Lantheus
LNTH
+$3.48M
3
ESPR
Esperion Therapeutics
ESPR
+$3.45M
4
DXCM icon
DexCom
DXCM
+$3.28M
5
LIVN icon
LivaNova
LIVN
+$3.12M

Sector Composition

Rank Sector Weight
1 Healthcare 79.05%
2 Financials 10.08%
3 Industrials 0.61%
4 Consumer Staples 0.24%
5 Communication Services 0.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACET icon
51
Adicet Bio
ACET
$74.7M
$2.13M 0.78%
9,375
– –
INSP icon
52
Inspire Medical Systems
INSP
$1.74B
$2.13M 0.78%
12,000
-12,000
-50% -$2.41M
TSVT
53
DELISTED
2seventy bio
TSVT
$2.04M 0.75%
140,000
+57,000
+69% +$846K
TGVCU
54
DELISTED
TG Venture Acquisition Corp. Units
TGVCU
$2.02M 0.74%
200,000
– –
NBIX icon
55
Neurocrine Biosciences
NBIX
$16.6B
$2.02M 0.74%
19,000
-3,000
-14% -$304K
LBBB
56
DELISTED
Lakeshore Acquisition II Corp. Ordinary Shares
LBBB
$2.02M 0.74%
+200,000
New +$2M
JYAC
57
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
$1.99M 0.73%
200,000
– –
QURE icon
58
uniQure
QURE
$3.22B
$1.97M 0.72%
+105,000
New +$2.21M
COLL icon
59
Collegium Pharmaceutical
COLL
$956M
$1.86M 0.68%
116,000
– –
VCEL icon
60
Vericel Corp
VCEL
$2.31B
$1.86M 0.68%
+80,000
New +$2.18M
AFMD
61
DELISTED
Affimed
AFMD
$1.85M 0.68%
+90,000
New +$2.5M
TVRD
62
Tvardi Therapeutics
TVRD
$23.4M
$1.81M 0.66%
5,361
-4,450
-45% -$1.61M
EYPT icon
63
EyePoint Inc
EYPT
$1.2B
$1.78M 0.65%
224,541
– –
MDWD icon
64
MediWound
MDWD
$185M
$1.77M 0.65%
+182,421
New +$2.3M
UBX
65
DELISTED
Unity Biotechnology
UBX
$1.69M 0.62%
+427,000
New +$2.69M
HLMN icon
66
Hillman Solutions
HLMN
$1.79B
$1.67M 0.61%
221,000
– –
TRVI icon
67
Trevi Therapeutics
TRVI
$2.63B
$1.64M 0.6%
1,066,157
-217,843
-17% -$714K
GOSS icon
68
Gossamer Bio
GOSS
$87M
$1.62M 0.59%
135,000
-125,000
-48% -$1.55M
CSTL icon
69
Castle Biosciences
CSTL
$979M
$1.56M 0.57%
+60,000
New +$1.68M
ALKS icon
70
Alkermes
ALKS
$8.25B
$1.56M 0.57%
70,000
+52,000
+289% +$1.35M
DHACU
71
DELISTED
Digital Health Acquisition Corp. Unit
DHACU
$1.54M 0.57%
150,000
– –
ADRT
72
DELISTED
Ault Disruptive Technologies Corporation
ADRT
$1.51M 0.55%
150,000
– –
FATBW
73
DELISTED
FAT Brands Inc. Warrant
FATBW
$1.17M 0.43%
227,000
– –
QTRX icon
74
Quanterix
QTRX
$190M
$1.05M 0.38%
+95,000
New +$1.21M
LRMR icon
75
Larimar Therapeutics
LRMR
$432M
$1.02M 0.38%
+320,000
New +$802K
1 2
3
4 5

Similar funds

TA
TLS Advisors Miami, Florida $42.1M AUM 25.99% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
VEPM
Vista Equity Partners Management San Francisco, California $42.7M AUM 16.65% 1-Year Est. Return
BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
VAM
Vazirani Asset Management New York $43.4M AUM 84.05% 1-Year Est. Return
SCM
Stadium Capital Management New Canaan, Connecticut $40.6M AUM 5.83% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
ICP
Indus Capital Partners New York $39.7M AUM 53.95% 1-Year Est. Return

Altium Capital Management's Q3 2022 Portfolio in Review

As of Q3 2022, Altium Capital Management held 166 positions worth $273M, up 9.1% from $250M the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Altium Capital Management's Q3 2022 filing shows 40 new, 8 increased, 21 reduced and 31 closed positions. Its largest new stake was BioLineRX: 103,732 shares worth $3.84M. The largest sale was STAAR Surgical, an estimated $5.32M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 74% a quarter earlier, followed by Financials and Industrials.

  • Altium Capital Management's largest Q3 2022 buy was BioLineRX: 103,732 shares worth $3.84M.
  • Altium Capital Management added most to AngioDynamics in Q3 2022, an estimated $3.41M increase.
  • Altium Capital Management's biggest Q3 2022 reduction was Lantheus, cutting an estimated $3.48M.
  • Altium Capital Management fully exited STAAR Surgical in Q3 2022, selling an estimated $5.32M.
  • Altium Capital Management's ten largest holdings make up 27% of its $273M portfolio in Q3 2022.
  • Altium Capital Management opened 40 new positions and closed 31 in Q3 2022.
  • Altium Capital Management's portfolio value rose 9.1% quarter-over-quarter to $273M.

Based on Altium Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.